Key facts
- It has raised $2.2M; the latest was Seed Round ($730K) in Oct 2025.
- Notable investors include Peregrine Ventures, Illumina.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Terrapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Terrapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Terrapeutics
Developer of a drug discovery platform designed to screen for drugs against other challenging targets. The company's platform offers an approach to discovering small therapeutic molecules from soil that is based on the intelligence of nature, enabling healthcare professionals to have a platform for ascending reticular activating system (RAS) inhibitors and infectious diseases drug discovery.
- Sector
- Healthcare
- HQ
- Jerusalem, Israel
- Founded
- 2019
- Employees
- 7
- Website
- terrapeuticspharma.com/
- Ownership
- Privately Held (backing)
Terrapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Terrapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Terrapeutics in its N-PORT filings yet. We sweep new filings monthly.